Efficacy of generic levetiracetam (epiterra) in monotherapy for epilepsy in adult patients: preliminary results

Objective: to evaluate the efficacy and tolerability of levetiracetam (LEV) (epiterra, TEVA) in adult patients with focal epilepsy (FE) or juvenile myoclonic epilepsy (JME) who took the drug for і6 months as of December 15, 2014.
Patients and methods. The efficacy of LEV as a generic (epiterra) used in monotherapy was analyzed in 23 patients with FE and in 4 female patients with JME who had taken the drug for ≥6 months. In FE, LEV was switched to epiterra because of the high cost of the former and inadequate efficacy/poor tolerability of initial antiepileptic drugs (AEDs) in 17 and 6 cases, respectively. In JMA, epiterra was prescribed as initial therapy in 2 cases and, with the diagnosis being changed, in 2 more patients. 
Results and discussion. When LEV was switched to its generic, the indicators of efficacy, tolerability, quality of life, and a plain electroencephalogram (EEG) were significantly unchanged. When epiterra was substituted for other AEDs, the efficiency of its therapy was also significantly unchanged and tolerance, quality of life, and EEG characteristics were improved. Epiterra’s adverse reactions as sleepiness (n = 1) and a higher rate of mental processes (n=1) were observed exclusively when it was switched from another AED. However, they were transient (for 2–3 weeks) and seen during either dose adjustment or at the stage of transitional combined therapy. Dual therapy (valproate + epiterra) had to be used in only 1 female patient. 

Thus, the 6-month use of epiterra in adult patients with FE as an alternative to brand LEV did not deteriorate the clinical picture of the disease (remission rates and injury frequency and severity were significantly unchanged) baseline tolerability, quality of life, or plain EEG values. The findings suggest that the use of epiterra is highly promising in epileptology, particularly in FE and JME in adult patients. 

1. Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord. 2003 May;5 Suppl 1:S17–26.

2. Shorvon SD. Levetiracetam. In: Handbook of epilepsia treatment. Oxford: Blackwell Sci. Ltd; 2000. P. 186–99.

3. Зенков ЛР. Изменения ЭЭГ в процессе лечения эпилепсии леветирацетамом (Кеппра). Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;(11;2):70–7. [Zenkov LR. The EEG changes during treatment of epilepsy levetiracetam (Keppra). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;(11;2):70–7. (In Russ.)].

4. Карлов ВА, Власов ПН. Эффективность кеппры в составе комплексной терапии при фармакорезистентной эпилепсии у взрослых. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(7):38–44. [Karlov VA, Vlasov PN. The effectiveness of keppra in the complex therapy with drug-resistant epilepsy in adults. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;105(7):38–44. (In Russ.)].

5. Карлов ВА, Власов ПН, Камелькова ЕГ, Шахабасова ЗС. Длительная монотерапия леветирацетамом парциальной эпилепсии у взрослых. Неврология нейропсихиатрия психосоматика. 2012;(S1):43–7. [Karlov VA, Vlasov PN, Kamel'kova EG, Shakhabasova ZS. Long-term levetiracetam monotherapy for partial epilepsy in adults. Nevrologiya neiropsikhiatriya psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2012;(S1):43–7. (In Russ.).] DOI: http://dx.doi.org/10.14412/2074-27112012-2498

6. Мухин КЮ, Пилия СВ, Чадаев ВА и др. Кеппра в лечении эпилепсии: эффективность и переносимость. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(1):49–51. [Mukhin KYu, Piliya SV, Chadaev VA, et al. Keppra in the treatment of epilepsy: efficacy and tolerability. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;105(1):49–51. (In Russ.)].

7. Зенков ЛР. Нейропатофизиология эпилептических энцефалопатий и непароксизмальных эпилептических расстройств и принципы их лечения. Неврология нейропсихиатрия психосоматика. 2010;(2):26–32. [Zenkov LR. Neuropathology of epileptic encephalopathies and non-paroxysmal epileptic disorders and principles of their treatment. Nevrologiya neiropsikhiatriya psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2010;(2):26–32. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2010-80

8. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551–63. DOI: 10.1111/epi.12074. Epub 2013 Jan 25.

9. Рекомендации Экспертного совета Российской Противоэпилептической Лиги по применению оригинальных и воспроизведенных препаратов (дженериков) для лечения эпилепсии. Эпилепсия и пароксизмальные состояния. 2011;(1):17–9. [Recommendations of the Expert Council of the Russian Antiepileptic League on the application of original and reproduced pharmaceuticals (generics) for the treatment of epilepsy. Epilepsiya i paroksizmal'nye sostoyaniya. 2011;(1):17–9. (In Russ.)].

10. Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resuling in icreased incidence of breakthrough seizures. Ann Pharmacother. 2011 May;45(5):e27. DOI: 10.1345/aph.1P765. Epub 2011 Apr 26.

11. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure. 2014 May;23(5):371–6. DOI: 10.1016/j.seizure.2014.02.003. Epub 2014 Feb 17.

12. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy. Results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013 Jan 22;80(4):400–5. DOI: 10.1212/WNL.0b013e31827f0874. Epub 2013 Jan 9.

13. Vajda FJ, O'Brien T, Lander C, et al. The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. Epilepsia. 2014 Aug;55(8):1229–34. DOI: 10.1111/epi.12711. Epub 2014 Jul 3.

14. Hagemann A, May TW, Nieder E, et al. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Res. 2013 Mar;104(1–2):140–50. DOI: 10.1016/j.eplepsyres.2012.08.005. Epub 2012 Sep 6.

15. Goldberg-Stern H, Feldman L, EidlitzMarkus T, et al. Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram – a pilot study. Eur J Paediatr Neurol. 2013 May;17(3):248–53. DOI: 10.1016/j.ejpn.2012.10.008. Epub 2012 Nov 16.